Nokia Corporation: Repurchase of own shares on 30.01.2025 Nokia CorporationStock Exchange Release30 January 2025 at 22:30 EET Nokia Corporation: Repurchase of own shares on 30.01.2025 Espoo, Finland – On 30 January 2025 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL872,0934.53CEUX--BATE--AQEU--TQEX--Total872,0934.53 * Rounded to two decimals On 22 November 2024, Nokia announced that its Board of Directors is initiating a share buyback program to offs...
Sales trends are turning positive after six negative quarters. While Nokia’s adj. EBIT guidance for 2025 fell shy of Infront consensus, it has now de-risked the case, mainly driven by investments to strengthen the data centre growth outlook. We reiterate our BUY, have raised our target price to EUR5.4 (5.2), and lowered our adj. EBIT for 2025–2026e by 8–1%. We see: 1) accelerated earnings momentum, with adj. EBIT growth of 18% YOY for its core divisions in 2025e; 2) the data centre story potenti...
Rdos. 4T'24 vs 4T'23: Ventas: 5.983 M euros (+4,8% vs +4,3% BS(e) y +0,7% consenso); EBIT: 1.142 M euros (+35,0% vs +15,6% BS(e) y +13,5% consenso); BDI: 977,0 M euros (+72,0% vs +24,8% BS(e) y +26,8% consenso). Rdos. 2024 vs 2023: Ventas: 19.442 M euros (-12,7% vs -12,8% BS(e) y -13,7% consenso); EBIT: 2.616 M euros (+10,1% vs +3,2% BS(e) y +2,5% consenso); BDI: 2.154 M euros (+32,7% vs +16,2% BS(e) y +16,9% consenso). A
4Q'24 vs. 4Q'23 Results NII: € 2.74 Bn (-0.3% vs. -1.8% BS(e) and -1.3% consensus); Total Revenues: € 4.08 Bn (+15.2% vs. +10.5% BS(e) and +12.6% consensus); Operating Income: € 2.54 Bn (+21% vs. +11.9% BS(e) and +17.0% consensus); Net Profit pre AT1: € 1.54 Bn (+33% vs. +16.4% BS(e) and +22.2% consensus). 4Q'24 vs. 3Q'24 Results NII: € 2.74 Bn (-1.9% vs. -3.4% BS(e) and -2.9% consensus); Total Revenues: € 4.08 Bn (-0.3% vs. -4.4% BS(e) and -2.5% consensus); Operating Income: € 2.54 Bn (-0.9% vs...
Rdos. 4T'24 vs 4T'23: Ventas: 10.564 M euros (-3,3% vs -3,3% BS(e) y -4,8% consenso); EBIT: 2.078 M euros (-19,6% vs -17,0% BS(e) y -19,6% consenso). Rdos. 2024 vs 2023: Ventas: 41.081 M euros (-4,6% vs -4,6% BS(e) y -5,0% consenso); EBIT: 11.343 M euros (-10,5% vs -10,0% BS(e) y -10,5% consenso).
Rdos. 4T'24 vs 4T'23: M. Intereses: 2.741 M euros (-0,3% vs -1,8% BS(e) y -1,3% consenso); M. Bruto: 4.080 M euros (+15,2% vs +10,5% BS(e) y +12,6% consenso); M. Neto: 2.535 M euros (++21% vs +11,9% BS(e) y +17,0% consenso); BDI pre AT1: 1.539 M euros (+33% vs +16,4% BS(e) y +22,2% consenso). Rdos. 4T'24 vs 3T'24: M. Intereses: 2.741 M euros (-1,9% vs -3,4% BS(e) y -2,9% consenso); M. Bruto: 4.080 M euros (-0,3% vs -4,4% BS(e) y -2,5% consenso); M. Neto: 2.535 M euros (-0,9% vs -8,3% BS(e) y -4,...
NEWS SUMMARY: CAIXABANK, OHLA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 4Q’24 results to be released over the coming days in Spain. Results spur buying ahead of Fed Except for the slight drop in the CAC, European stock markets posted gains ahead of the Fed meeting, which kept rates in the range of 4.25%-4.50%, as expected. In the STOXX 600, the gains were led by Technolo...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CAIXABANK, OHLA. EUROPA: NOKIA, SANOFI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’24 que se publicarán en España y Europa en los próximos días. Los resultados impulsan las compras antes de la Fed A excepción de la ligera caída del CAC las bolsas europeas se decantaron por subidas antes de la decisió...
Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of 10.3% at CER1 and business EPS2 of €1.31 Pharma launches up 56.5%, reaching sales of €0.8 billion, 8% of total sales, led by ALTUVIIIODupixent sales up 16.0% to €3.5 billionVaccines sales up 10.8% to €2.2 billion, driven by Beyfortus sales in EuropeBusiness EPS of €1.31, -11.0% at CER and -14.9% report...
Communiqué de presse : Croissance des ventes de 10,3% au T4. Objectif du BNPA des activités de 2024 dépassé. Fort rebond du BNPA des activités attendu en 2025 Sanofi: Croissance des ventes de 10,3% au T4. Objectif du BNPA des activités de 2024 dépassé. Fort rebond du BNPA des activités attendu en 2025 Paris, le 30 janvier 2025 T4 : Croissance des ventes de 10,3 % à TCC(1) et BNPA(2) des activités de €1,31 Les lancements pharmaceutiques soutenus par ALTUVIIIO progressent de 56,5 %, atteignant 0,8 milliard d’euros et contribuant à hauteur de 8% du chiffre d’affaires Les ventes de Dupixent...
Proposals by the Board of Directors to Nokia Corporation’s Annual General Meeting 2025 Nokia CorporationStock Exchange Release30 January 2025 at 8:10 EET Proposals by the Board of Directors to Nokia Corporation’s Annual General Meeting 2025Nokia Corporation’s Annual General Meeting will be held on Tuesday 29 April 2025 at 13:00 (EEST) at Finlandia Hall, Helsinki, Finland. The Board submits the following proposals to the Annual General Meeting. Complete proposals are available as of today at /agm2025. The notice of the Annual General Meeting with more detailed information on the participati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.